Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Mateusz Maligłówka
 -- 1953 2022-04-01 09:44:21 |
2 format
Jason Zhu
 -23 word(s) 1930 2022-04-02 04:17:42 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Maligłówka, M.; Kosowski, M.; Hachuła, M.; Cyrnek, M.; Buldak, L.; Basiak, M.; Bołdys, A.; Machnik, G.; Bułdak, R.; Okopień, B. Proprotein Convertase Subtilisin/Kexin Type 9 and Infections. Encyclopedia. Available online: https://encyclopedia.pub/entry/21262 (accessed on 18 November 2024).
Maligłówka M, Kosowski M, Hachuła M, Cyrnek M, Buldak L, Basiak M, et al. Proprotein Convertase Subtilisin/Kexin Type 9 and Infections. Encyclopedia. Available at: https://encyclopedia.pub/entry/21262. Accessed November 18, 2024.
Maligłówka, Mateusz, Michał Kosowski, Marcin Hachuła, Marcin Cyrnek, Lukasz Buldak, Marcin Basiak, Aleksandra Bołdys, Grzegorz Machnik, Rafał Bułdak, Bogusław Okopień. "Proprotein Convertase Subtilisin/Kexin Type 9 and Infections" Encyclopedia, https://encyclopedia.pub/entry/21262 (accessed November 18, 2024).
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Buldak, L., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R., & Okopień, B. (2022, April 01). Proprotein Convertase Subtilisin/Kexin Type 9 and Infections. In Encyclopedia. https://encyclopedia.pub/entry/21262
Maligłówka, Mateusz, et al. "Proprotein Convertase Subtilisin/Kexin Type 9 and Infections." Encyclopedia. Web. 01 April, 2022.
Proprotein Convertase Subtilisin/Kexin Type 9 and Infections
Edit

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is the last discovered member of the family of proprotein convertases (PCs), mainly synthetized in hepatic cells. This serine protease plays a pivotal role in the reduction of the number of low-density lipoprotein receptors (LDLRs) on the surface of hepatocytes, which leads to an increase in the level of cholesterol in the blood. 

Infections proprotein convertase subtilisin/kexin type 9 SARS-CoV-2 low-density lipoprotein receptors

1. Introduction

Proprotein convertases (PCs) are a family of nine serine proteases, which also includes proprotein convertase subtilisin/kexin type 9 (PCSK9). Each of those proteases plays a key role in post-translational modifications of propeptides leading to the formation of mature particles e.g., growth factors, enzymes, hormones, and transcriptional factors. Taking into consideration an ability for the activation of many substrates, to date, there seem to be a lot of physiological and pathophysiological processes that PCs take part in [1][2][3].

2. PCSK9 and Its Inhibitors

PCSK9, originally known as neural apoptosis-regulated convertase 1 (NARC-1), was discovered in 2003 by Seidah et al. [4]. It is synthetized in the endoplasmic reticulum (ER) of hepatic cells in the form of proenzyme, where after autocatalytic activation, it is transferred to plasma. The soluble PCSK9 binds to the epidermal growth factor homology domain A (EGF-A) of the low-density lipoprotein receptors (LDLRs) located mainly on the surface of hepatocytes, and makes them unable to attach low-density lipoprotein cholesterol (LDL-C) particles. In addition, it promotes the degradation of LDLRs by enhancing their endocytosis and blocking their recycling. Recent research shows that also intracellular PCSK9, before its exocytosis, can reduce the number of LDLRs (intracellular pathway) [2][5]. The targets for degradation by PCSK9 are also very-low-density lipoprotein receptors (VLDLRs) as particles from the close family to LDLRs [6]. The above-mentioned mechanisms lead to the impaired transport of cholesterol from the blood into cells and result in hypercholesterolemia. Furthermore, gain of function (GOF) mutations in PCSK9 genes are the cause of familial hypercholesterolemia with significantly higher levels of cholesterol in the blood [7], whereas loss-of-function mutations (LOF) are associated with hypocholesterolemia [8].
Among factors that affect the expression of PCSK9: age, gender, diet, aerobic exercises, pregnancy, diurnal rhythm, diseases of thyroid gland, kidneys and liver, type 2 diabetes mellitus (DM2), obesity, drugs (e.g., statins) [9][10].
The clinical benefit from discoveries concerning PCSK9 influence on lipid metabolism, was the implementation to the therapy of hypercholesterolemia, medications that inhibit function of PCSK9–monoclonal antibodies against circulating PCSK9 (PCSK9 mAbs: alirocumab and evolocumab) and inclisiran—a small interfering RNA (siRNA) which prevents from the translation of messenger RNA (mRNA) of PCSK9 and in that way decreases the production of mature protein in liver [11][12][13].
Monoclonal antibodies against PCSK9 have the ability to lower plasma LDL cholesterol (LDL-C) by 60% from the baseline. They also decrease the level of apolipoprotein B (apoB) by 50% and triglycerides (TGs) by 15%, and have a slight positive effect on plasma high-density lipoprotein cholesterol (HDL-C) level and increase it by 5–10%. In contrast to statin therapy, they reduce (by even 25%) the concentration of lipoprotein(a) (Lp(a)), which is acknowledged as an independent cardiovascular risk factor [14][15]. The lipid-lowering potential of inclisiran is similar to PCSK9 mAbs, especially with regard to LDL-C and Lp(a) levels [16]. A potential advantage of therapy with inclisiran in the maintenance of compliance results from chemical structure and mechanism of action which ensure longer duration of lipid-lowering effects and, thus, less frequent administration of the drug in comparison with PCSK9 mAbs [17][18]. On the other hand, in spite of the high lipid-lowering potential of PCSK9 inhibitors, therapy with those drugs is still limited, mainly because of the high cost, strict reimbursement criteria and the COVID-19 pandemic, which results in a decline in number of patients that achieve therapeutic goals concerning LDL-C concentration [19][20].
Figure 1 shows the cellular mechanism of PCSK9 and its inhibitors on cholesterol metabolism [21].
Metabolites 12 00256 g002 550
Figure 1. The cellular actions of PCSK9 and its inhibitors on cholesterol metabolism [21]. Abbreviations: ER, endoplasmatic reticulum; GA, Golgi apparatus; LDL, low-density lipoprotein; LDLR, low-density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; PCSK9 mAb, monoclonal antibody against PCSK9; siRNA, small interfering RNA (inclisiran). (A) LDLR gene is transcribed into mRNA, then translated within ER into mature protein and transferred on the cell surface. (B) LDL particles, after binding to the LDLRs on the cell surface, are internalized into an endosome. (C) As the endosome matures, LDL and LDLR decouple—LDLR (D) recycles, and LDL is catabolized in the lysosome (E). (F) PCSK9 gene is transcribed into mRNA and then translated within ER into the mature protein. It can bind to the LDLR intracellularly within Golgi apparatus (G) or be secreted to the extracellular space—both ways lead to lysosomal degradation of LDLR (H). (I) Inclisiran (siRNA) inhibits the translation of PCSK9 mRNA and prevents the formation of mature protein. (J) PCSK9 mAbs (e.g., alirocumab) bind to the soluble PCSK9 in the plasma and prevent from lysosomal degradation of LDLRs.
High efficacy in reducing the cardiovascular risk by PCSK9 mAbs observed in clinical trials (FOURIER, ODYSSEY Outcomes) seems not to be completely dependent on lipid-lowering effects [3]. The expression of PCSK9 in tissues not directly associated with cholesterol metabolism (e.g., endothelium, kidneys, pancreas, central nervous system), pleiotropic effects of other lipid-lowering drugs (e.g., statins) and multifunctional character of other proprotein convertases, were the reasons for proceeding studies on functions of PCSK9 that go beyond cholesterol metabolism [1][2][3][22][23].

3. Bacterial Infections

Lipid molecules which form the structure of bacterial cell membranes, e.g., lipopolysaccharides (LPS) and lipoteichoic acid, play the leading role in initiating the host immune response against pathogens [24]. Studies show that the response intensity is significantly related to the concentration of those lipids, and limiting it prevents the occurrence of septic shock. The clearing of bacterial lipid structures from the bloodstream occurs with the participation of LDLRs [25][24][26].
Results from the experimental sepsis model showed that overexpression in PCSK9 was characterized by greater bacterial dissemination and consequent organ pathology, particularly in the liver and lungs [27]. Others have proven a significant reduction in proinflammatory cytokines concentration after LPS exposure in the group of patients with PCSK9 LOF mutations [28]. The above-mentioned data lead to a hypothesis that using PCSK9 inhibitors may improve the prognosis of patients with severe bacterial infections. Currently, this assumption is being verified in a randomized placebo-controlled double-blind study with alirocumab (NCT03634293). The study will assess the difference in survival after 28 days in patients with sepsis or septic shock, treated with PCSK9i or placebo in an intensive care unit (ICU). The results might introduce a novel group of drugs to the therapy of severe bacterial infections [29].

4. Viral Infections:

Flu-like symptoms and an increased number of upper respiratory tract infections have been reported as side effects in clinical trials with PCSK9 inhibitors [30][31]. So far, it has not been possible to explicitly confirm or contradict that PCSK9 is directly involved in the pathogenesis of viral diseases [32]. Considering the fact that the pathogenesis of viral infections involves many host factors, e.g., lipids and lipoproteins [33], the influence of PCSK9 inhibitors on the course of viral infections has captured the attention of many scientists all over the world.

4.1. Hepatitis C Virus

Hepatitis C virus (HCV) infection is a crucial cause of severe liver disease leading to chronic hepatitis, cirrhosis and hepatocellular carcinoma. The World Health Organization estimates that seventy-one million people have HCV infection worldwide and at least 400,000 people die of it every year [34].
HCV enters hepatocytes with the use of different proteins—one of them is LDLR [35]. Syed GH et al. observed that hepatic cells infected by HCV contain more LDLRs than those from the control group [36]. Some studies suggested that LDLR also plays a key role for the post-entry viral processes such as replication [37]. Furthermore, the report from an in vitro study revealed that LDLR degradation by PCSK9 with the participation of hepatic CD81 particle is one of the main ways in which HCV invades cells [38][39].
These results raised the concern that PCSK9 inhibitors might increase CD81 levels, and thereby susceptibility to HCV infection. In 2016, Ramanathan A. et al., in their in vitro and in vivo studies, did not confirm that treatment with alirocumab increased the risk of HCV infection or CD81 levels [40]. Moreover, analyses of the results of ten clinical trials, which compared the action of alirocumab with placebo or ezetimibe, showed no elevations in predisposition to HCV infection in the groups of participants treated with PCSK9i. [40] Additionally, the ODYSSEY and FOURIER clinical trials did not reveal statistically significant increases in the incidence of hepatic disorders [41][42].

4.2. Dengue Virus

Dengue fever is one of major global health problems, with 390 million individuals infected annually, and with a rate of mortality that may reach up to 20% [43][44]. Dengue virus (DENV) requires cholesterol in the development cycle: viral entry by membrane, fusion, and replication [45]. In vitro and animal models with statins revealed the reduction in DENV infections [46][47]. Unfortunately, lovastatin used in a clinical trial did not repeat this effectiveness in human [48]. New hopes appeared with the efficacy of lipid-lowering drugs from the group of PCSK9 inhibitors. Gan ES et al. reported that elevated PCSK9 levels are associated with higher viremia and an increased risk of a more severe course of dengue [49]. Clinical trials with PCSK9 inhibitors are required to test their potential effectiveness in a novel indication.

4.3. SARS-CoV-2

An interstitial pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, Hubei, China, in December 2019. As of 14 January 2022, over 318 million SARS-CoV-2 infections have been reported. So far, 5.5 million deaths have been associated with coronavirus disease 2019 (COVID-19). Cardiovascular diseases, arterial hypertension, hyperlipidemia, diabetes, kidney and chronic lung diseases, cancer and obesity have all been associated with severe course of the disease and increased mortality rate [50][51].
SARS-CoV-2 enters host cells using angiotensin converting enzyme 2 (ACE2) receptors and with the participation of cholesterol in trafficking ACE2 to the viral entry site [52]. There are some hypotheses suggesting that PCSK9 inhibitors, as the lipid-lowering drugs, could affect various elements in the pathophysiology of SARS-CoV-2 infection [52].
COVID-19 is associated with increased incidence of coagulation abnormalities and higher risk of venous thromboembolic disease [53]. An analysis of clinical trials (FOURIER and ODYSSEY OUTCOMES) reported lower rates of venous thromboembolism in patients who were treated with PCSK9 inhibitors compared with placebo [41][42].
Systemic endothelial inflammation is considered as one of the main causes of severe course of SARS-CoV-2 infection [54]. The positive correlation between LDL plasma concentration and endothelial dysfunction is widely known [55]. Some studies have confirmed that PCSK9 inhibitors improves the functioning of the endothelium in patients with inflammatory diseases [56][57]. In the ODYSSEY FH I and FH study, PCSK9 inhibitors decreased the level of the atherothrombogenic Lp(a) by approximately 30% [58]. The observation by Huang W et al. showed a negative correlation between PCSK9 expression and the risk of infection with SARS-CoV2 [59]. Further studies are required to unequivocally assess the potentially beneficial effects of PCSK9 inhibitors in the therapy for COVID-19.

5. Parasites

Parasites the organisms that need cholesterol to develop properly. As they lack the ability to synthesize it de novo, they use cholesterol from the host [60].
Arama C et al. examined the influence of GOF mutations in PCSK9 on the course of malaria. The study revealed that in a group of 752 Malians children, those who were GOF mutation carriers were prone to a more severe course of disease [61]. In the research of Fedoryak O et al., LOF mutations in PCSK9 were associated with reduced mortality in the course of malaria [62]. According to their results, a hypothesis that PCSK9 inhibitors could be useful for the therapy and prevention of malaria was formed. To date, there is no scientific evidence confirming the association between the therapy with PCSK9 inhibitors and the course of malaria. Further studies are required.

References

  1. Seidah, N.G.; Prat, A. The biology and therapeutic targeting of the proprotein convertases. Nat. Rev. Drug Discov. 2012, 11, 367–383.
  2. Małuch, I.; Walewska, A.; Sikorska, E.; Prahl, A. Konwertazy probiałkowe—Rodzina proteaz serynowych o szerokim spektrum funkcji fizjologicznych. Post. Bioch. 2016, 62, 472–481.
  3. Seidah, N.G.; Prat, A. The multifaceted biology of PCSK9. Endocr. Rev. 2021, bnab035.
  4. Seidah, N.G.; Benjannet, S.; Wickham, L.; Marcinkiewicz, J.; Jasmin, S.B.; Stifani, S.; Basak, A.; Prat, A.; Chretien, M. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 2003, 100, 928–933.
  5. Shrestha, P.; van de Sluis, B.; Dullaart, R.P.F.; van den Born, J. Novel aspects of PCSK9 and lipoprotein receptors in renal disease-related dyslipidemia. Cell Signal. 2019, 55, 53–64.
  6. Poirier, S.; Mayer, G.; Benjannet, S.; Bergeron, E.; Marcinkiewicz, J.; Nassoury, N.; Mayer, H.; Nimpf, J.; Prat, A.; Seidah, N.G. The proprotein convertase PCSK9 induces the degradation of low-density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J. Biol. Chem. 2008, 283, 2363–2372.
  7. Abifadel, M.; Varret, M.; Rabés, J.P.; Allard, D.; Ouguerram, K.; Devillers, M.; Cruaud, C.; Benjannet, S.; Wickham, L.; Erlich, D.; et al. Mutations in PCSK-9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 2003, 34, 154–156.
  8. Uribe, K.B.; Chemello, K.; Larrea-Sebal, A.; Benito-Vicente, A.; Galicia-Garcia, U.; Bourane, S.; Jaafar, A.K.; Lambert, G.; Martín, C. A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. Int. J. Mol. Sci. 2021, 22, 13602.
  9. Schlüter, K.D.; Wolf, A.; Schreckenberg, R. Coming Back to Physiology: Extra Hepatic Functions of Proprotein Convertase Subtilisin/Kexin Type 9. Front. Physiol. 2020, 11, 598649.
  10. Cui, C.J.; Li, S.; Li, J.J. PCSK9 and its modulation. Clin. Chim. Acta 2015, 440, 79–86.
  11. Robinson, J.G.; Farnier, M.; Krempf, M.; Bergeron, J.; Luc, G.; Averna, M.; Stroes, E.S.; Langslet, G.; Raal, F.J.; El Shahawy, M.; et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015, 372, 1489–1499.
  12. Zhang, X.L.; Zhu, Q.Q.; Zhu, L.; Chen, J.Z.; Chen, Q.H.; Li, G.N.; Xie, J.; Kang, L.N.; Xu, B. Safety and efficacy of anti-PCSK9 antibodies: A meta-analysis of 25 randomized, controlled trials. BMC Med. 2015, 13, 123.
  13. Lamb, Y.N. Inclisiran: First Approval. Drugs 2021, 81, 389–395.
  14. Sabatine, M.S. PCSK9 inhibitors: Clinical evidence and implementation. Nat. Rev. Cardiol. 2019, 16, 155–165.
  15. Gencer, B.; Kronenberg, F.; Stroes, E.S.; Mach, F. Lipoprotein(a): The revenant. Eur. Heart J. 2017, 38, 1553–1560.
  16. Hardy, J.; Niman, S.; Pereira, E.; Lewis, T.; Reid, J.; Choksi, R.; Goldfaden, R.F. A Critical Review of the Efficacy and Safety of Inclisiran. Am. J. Cardiovasc. Drugs 2021, 21, 629–642.
  17. Banerjee, Y.; Pantea Stoian, A.; Cicero, A.; Fogacci, F.; Nikolic, D.; Sachinidis, A.; Rizvi, A.A.; Janez, A.; Rizzo, M. Inclisiran: A small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opin. Drug Saf. 2022, 21, 9–20.
  18. Giglio, R.V.; Pantea Stoian, A.; Al-Rasadi, K.; Banach, M.; Patti, A.M.; Ciaccio, M.; Rizvi, A.A.; Rizzo, M. Novel Therapeutical Approaches to Managing Atherosclerotic Risk. Int. J. Mol. Sci. 2021, 22, 4633.
  19. Nguy, J.; Hitchen, S.A.; Lan, N.; Dwivedi, G.; Larbalestier, R.; Yeap, B.B.; Fegan, P.G. Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularization. Intern. Med. J. 2022. epub ahead of print.
  20. Caso, V.M.; Sperlongano, S.; Liccardo, B.; Romeo, E.; Padula, S.; Arenga, F.; D’Andrea, A.; Caso, P.; Golino, P.; Nigro, G. The Impact of the COVID-19 Outbreak on Patients’ Adherence to PCSK9 Inhibitors Therapy. J. Clin. Med. 2022, 11, 475.
  21. German, C.A.; Shapiro, M.D. Small interfering RNA therapeutic inclisiran: A new approach to targeting PCSK9. BioDrugs 2020, 34, 1–9.
  22. Steffens, D.; Bramlage, P.; Scheeff, C.; Kasner, M.; Hassanein, A.; Friebel, J.; Rauch-Kröhnert, U. PCSK9 inhibitors and cardiovascular outcomes. Expert Opin. Biol. Ther. 2020, 20, 35–47.
  23. Oesterle, A.; Laufs, U.; Liao, J.K. Pleiotropic Effects of Statins on the Cardiovascular System. Circ. Res. 2017, 120, 229–243.
  24. Savva, A.; Roger, T. Targeting toll-like receptors: Promising therapeutic strategies for the management of sepsis-associated pathology and infectious diseases. Front. Immunol. 2013, 4, 387.
  25. Van Amersfoort, E.S.; Van Berkel, T.J.; Kuiper, J. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin. Microbiol. Rev. 2003, 16, 379–414.
  26. Levels, J.H.; Marquart, J.A.; Abraham, P.R.; van den Ende, A.E.; Molhuizen, H.O.; van Deventer, S.J.; Meijers, J.C. Lipopolysaccharide is transferred from high-density to low-density lipoproteins by lipopolysaccharide-binding protein and phospholipid transfer protein. Infect. Immun. 2005, 73, 2321–2326.
  27. Dwivedi, D.J.; Grin, P.M.; Khan, M.; Prat, A.; Zhou, J.; Fox-Robichaud, A.E.; Seidah, N.G.; Liaw, P.C. Differential Expression of PCSK9 Modulates Infection, Inflammation, and Coagulation in a Murine Model of Sepsis. Shock 2016, 46, 672–680.
  28. Walley, K.R.; Thain, K.R.; Russell, J.A.; Reilly, M.P.; Meyer, N.J.; Ferguson, J.F.; Christie, J.D.; Nakada, T.A.; Fjell, C.D.; Thair, S.A.; et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci. Transl. Med. 2014, 6, 258ra143.
  29. Available online: https://clinicaltrials.gov/ct2/show/NCT03634293 (accessed on 15 January 2022).
  30. Blom, D.J.; Hala, T.; Bolognese, M.; Lillestol, M.J.; Toth, P.D.; Burgess, L.; Ceska, R.; Roth, E.; Koren, M.J.; Ballantyne, C.M.; et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N. Engl. J. Med. 2014, 370, 1809–1819.
  31. Giugliano, R.P.; Desai, N.R.; Kohli, P.; Rogers, W.J.; Somaratne, R.; Huang, F.; Liu, T.; Mohanavelu, S.; Hoffman, E.B.; McDonald, S.T.; et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet 2012, 380, 2007–2017.
  32. Khademi, F.; Momtazi-Borojeni, A.A.; Reiner, Ž.; Banach, M.; Al-Rasadi, K.A.; Sahebkar, A. PCSK9 and infection: A potentially useful or dangerous association? J. Cell Physiol. 2018, 233, 2920–2927.
  33. Ploss, A.; Evans, M.J. Hepatitis C virus host cell entry. Curr. Opin. Virol. 2012, 2, 14–19.
  34. Roger, S.; Ducancelle, A.; Le Guillou-Guillemette, H.; Gaudy, C.; Lunel, F. HCV virology and diagnosis. Clin. Res. Hepatol. Gastroenterol. 2021, 45, 101626.
  35. Burlone, M.E.; Budkowska, A. Hepatitis C virus cell entry: Role of lipoproteins and cellular receptors. J. Gen. Virol. 2009, 90, 1055–1070.
  36. Syed, G.H.; Tang, H.; Khan, M.; Hassanein, T.; Liu, J.; Siddiqui, A. Hepatitis C virus stimulates low-density lipoprotein receptor expression to facilitate viral propagation. J. Virol. 2014, 88, 2519–2529.
  37. Albecka, A.; Belouzard, S.; Op de Beeck, A.; Descamps, V.; Goueslain, L.; Bertrand-Michel, J.; Tercé, F.; Duverlie, G.; Rouillé, Y.; Dubuisson, J. Role of low-density lipoprotein receptor in the hepatitis C virus life cycle. Hepatology 2012, 55, 998–1007.
  38. Labonté, P.; Begley, S.; Guévin, C.; Asselin, M.C.; Nassoury, N.; Mayer, G.; Prat, A.; Seidah, N.G. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology 2009, 50, 17–24.
  39. Le, Q.T.; Blanchet, M.; Seidah, N.G.; Labonté, P. Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low-Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. J. Biol. Chem. 2015, 290, 23385–23400.
  40. Ramanathan, A.; Gusarova, V.; Stahl, N.; Gurnett-Bander, A.; Kyratsous, C.A. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. PLoS ONE 2016, 11, e0154498.
  41. Schwartz, G.G.; Steg, P.G.; Szarek, M.; Bhatt, D.L.; Bittner, V.A.; Diaz, R.; Edelberg, J.M.; Goodman, S.G.; Hanotin, C.; Harrington, R.A.; et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N. Engl. J. Med. 2018, 379, 2097–2107.
  42. Sabatine, M.S.; Giugliano, R.P.; Keech, A.C.; Honarpour, N.; Wiviott, S.D.; Murphy, S.A.; Kuder, J.F.; Wang, H.; Liu, T.; Wasserman, S.M.; et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N. Engl. J. Med. 2017, 376, 1713–1722.
  43. Bhatt, S.; Gething, P.W.; Brady, O.J.; Messina, J.P.; Farlow, A.W.; Moyes, C.L.; Drake, J.M.; Brownstein, J.S.; Hoen, A.G.; Sankoh, O.; et al. The global distribution and burden of dengue. Nature 2013, 496, 504–507.
  44. Simmons, C.P.; Farrar, J.J.; Nguyen, V.V.; Wills, B. Dengue. N. Engl. J. Med. 2012, 366, 1423–1432.
  45. Soto-Acosta, R.; Bautista-Carbajal, P.; Cervantes-Salazar, M.; Angel-Ambrocio, A.H.; Del Angel, R.M. DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target. PLoS Pathog. 2017, 13, e1006257.
  46. Bryan-Marrugo, O.L.; Arellanos-Soto, D.; Rojas-Martinez, A.; Barrera-Saldaña, H.; Ramos-Jimenez, J.; Vidaltamayo, R.; Rivas-Estilla, A.M. The anti-dengue virus properties of statins may be associated with alterations in the cellular antiviral profile expression. Mol. Med. Rep. 2016, 14, 2155–2163.
  47. Martinez-Gutierrez, M.; Correa-Londoño, L.A.; Castellanos, J.E.; Gallego-Gómez, J.C.; Osorio, J.E. Lovastatin delays infection and increases survival rates in AG129 mice infected with dengue virus serotype 2. PLoS ONE 2014, 9, e87412.
  48. Whitehorn, J.; Nguyen, C.V.V.; Khanh, L.P.; Kien, D.T.H.; Quyen, N.T.H.; Tran, N.T.T.; Hang, N.T.; Truong, N.T.; Hue Tai, L.T.; Cam Huong, N.T.; et al. Lovastatin for the Treatment of Adult Patients with Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin. Infect. Dis. 2016, 62, 468–476.
  49. Gan, E.S.; Tan, H.C.; Le, D.H.T.; Huynh, T.T.; Wills, B.; Seidah, N.G.; Ooi, E.E.; Yacoub, S. Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes. J. Clin. Investig. 2020, 130, 5223–5234.
  50. Available online: https://covid19.who.int/ (accessed on 15 January 2022).
  51. Mehra, M.R.; Desai, S.S.; Kuy, S.; Henry, T.D.; Patel, A.N. Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19. N. Engl. J. Med. 2020, 382, 2582.
  52. Barkas, F.; Milionis, H.; Anastasiou, G.; Liberopoulos, E. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019? Med. Hypotheses 2021, 146, 110452.
  53. Bikdeli, B.; Madhavan, M.V.; Jimenez, D.; Chuich, T.; Dreyfus, I.; Driggin, E.; Nigoghossian, C.; Ageno, W.; Madjid, M.; Guo, Y.; et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2020, 75, 2950–2973.
  54. Nägele, M.P.; Haubner, B.; Tanner, F.C.; Ruschitzka, F.; Flammer, A.J. Endothelial dysfunction in COVID-19: Current findings and therapeutic implications. Atherosclerosis 2020, 314, 58–62.
  55. Steinberg, H.O.; Bayazeed, B.; Hook, G.; Johnson, A.; Cronin, J.; Baron, A.D. Endothelial dysfunction is associated with cholesterol levels in the high normal range in humans. Circulation 1997, 96, 3287–3293.
  56. Leucker, T.M.; Gerstenblith, G.; Schär, M.; Brown, T.T.; Jones, S.R.; Afework, Y.; Weiss, R.G.; Hays, A.G. Evolocumab, a PCSK9-Monoclonal Antibody, Rapidly Reverses Coronary Artery Endothelial Dysfunction in People Living with HIV and People with Dyslipidemia. J. Am. Heart Assoc. 2020, 9, e016263.
  57. Available online: https://www.acc.org/latest-in-cardiology/articles/2020/10/02/12/59/are-pcsk9-inhibitors-the-next-front-line-therapies-to-improve-vascular-dysfunction (accessed on 15 January 2022).
  58. Kastelein, J.J.; Ginsberg, H.N.; Langslet, G.; Hovingh, G.K.; Ceska, R.; Dufour, R.; Blom, D.; Civeira, F.; Krempf, M.; Lorenzato, C.; et al. ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. Eur. Heart J. 2015, 36, 2996–3003.
  59. Huang, W.; Xiao, J.; Ji, J.; Chen, L. Association of lipid-lowering drugs with COVID-19 outcomes from a Mendelian randomization study. elife 2021, 10, e73873.
  60. Mbikay, M.; Mayne, J.; Seidah, N.G.; Chrétien, M. Of PCSK9, cholesterol homeostasis and parasitic infections: Possible survival benefits of loss-of-function PCSK9 genetic polymorphisms. Med. Hypotheses 2007, 69, 1010–1017.
  61. Arama, C.; Diarra, I.; Kouriba, B.; Sirois, F.; Fedoryak, O.; Thera, M.A.; Coulibaly, D.; Lyke, K.E.; Plowe, C.V.; Chrétien, M.; et al. Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. PLoS ONE 2018, 13, e0192850.
  62. Fedoryak, O.; Arama, C.; Diarra, I.; Kouriba, B.; Chrétien, M.; Mbikay, M. Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children. Can. J. Infect. Dis. Med. Microbiol. 2020, 9340480.
More
©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Cardiac & Cardiovascular Systems
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Mateusz Maligłówka
,
Michał Kosowski
,
Marcin Hachuła
,
Marcin Cyrnek
,
Lukasz Buldak
,
Marcin Basiak
,
Aleksandra Bołdys
,
Grzegorz Machnik
,
Rafał Bułdak
,
Bogusław Okopień
View Times: 394
Revisions: 2 times (View History)
Update Date: 02 Apr 2022
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback